CKD animals treated with the NOX1/4 inhibitor GKT and the calcimimetic drug KP demonstrated decreased calcification, 8‐OHdG, and NOX4 expression in the vasculature, decreased PTH, and increased cFGF23. This evidence concerns the gene NOX1 and chronic kidney disease.